Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N + disease treated with maximal androgen blockade as a primary treatment

British Journal of Urology

Volumn 79, Issue 5, 1997, Pages 808-809

  Palmberg, C ^a   Kylmala, T ^a   Tammela, T ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANDROGEN; BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE SCINTISCANNING; CASE REPORT; DIARRHEA; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; METABOLIC DISORDER; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; URINE RETENTION;

EID: 0031395342     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00197.x     Document Type: Article

References (4)

1. Benson R. Total androgen blockade: the United States experience. Eur Urol 1993: 24 (Suppl 2): 72-6
2. Debruyne FMJ, Dijkman GA. Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 1995; 28: 177-88
3. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155: 209-12
4. Schellhammer P. Sharifi R, Block N et al. Controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 1995; 45: 745-52